John Addington Wilson Sells 9,603 Shares of Rapid Micro Biosystems (NASDAQ:RPID) Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) COO John Addington Wilson sold 9,603 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total transaction of $41,484.96. Following the completion of the sale, the chief operating officer directly owned 316,762 shares of the company’s stock, valued at approximately $1,368,411.84. This trade represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rapid Micro Biosystems Stock Down 21.9%

NASDAQ RPID traded down $0.96 during trading on Thursday, reaching $3.42. 514,590 shares of the company’s stock traded hands, compared to its average volume of 133,521. Rapid Micro Biosystems, Inc. has a 12-month low of $1.86 and a 12-month high of $4.94. The company has a debt-to-equity ratio of 0.42, a current ratio of 4.23 and a quick ratio of 2.95. The firm has a market cap of $151.58 million, a price-to-earnings ratio of -3.39 and a beta of 1.38. The company’s 50 day simple moving average is $3.97 and its two-hundred day simple moving average is $3.54.

Rapid Micro Biosystems (NASDAQ:RPID) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). The business had revenue of $11.28 million for the quarter, compared to the consensus estimate of $10.93 million. Rapid Micro Biosystems had a negative net margin of 145.11% and a negative return on equity of 73.90%. As a group, sell-side analysts forecast that Rapid Micro Biosystems, Inc. will post -1.1 EPS for the current fiscal year.

More Rapid Micro Biosystems News

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: New multi-system order from Samsung Biologics reinforces commercial traction for the Growth Direct automation platform and expands deployment across a large CDMO customer network — a clear revenue-growth catalyst. Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics
• Positive Sentiment: Company reported record Q4 and full‑year 2025 revenue (Q4 revenue $11.3M, FY2025 $33.6M), and Q4 revenue beat the Street — evidence demand and placements are growing. Rapid Micro Biosystems Reports Record Fourth Quarter and Full-Year 2025 Financial Results
• Neutral Sentiment: Earnings call transcript and summaries provide color on growth initiatives and customer pipeline but did not materially change the near‑term outlook; read for management commentary on placements, margin drivers and execution risks. Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS missed expectations (reported ($0.28) vs. consensus ($0.23)), and profitability remains weak (large negative net margin and negative ROE) — these metrics keep the stock in a riskier profile and may slow multiple expansion. RPID Earnings / Conference Call
• Negative Sentiment: The company issued FY2026 revenue guidance of $37.0M–$41.0M (management expects ~30–38 system placements) — the midpoint is slightly below consensus (~$39.7M), which, combined with high operating losses, likely weighed on sentiment. 2026 Guidance in Press Release
• Negative Sentiment: Recent insider selling by CEO, CFO and COO (multiple Form 4 filings show sales in March) can amplify downward pressure on the stock even if sales are for diversification or liquidity. SEC Form 4 — Spignesi sale

Institutional Investors Weigh In On Rapid Micro Biosystems

Several institutional investors have recently added to or reduced their stakes in the business. Evernest Financial Advisors LLC grew its stake in shares of Rapid Micro Biosystems by 355.1% during the third quarter. Evernest Financial Advisors LLC now owns 200,234 shares of the company’s stock worth $669,000 after acquiring an additional 156,234 shares during the last quarter. Informed Momentum Co LLC acquired a new position in Rapid Micro Biosystems during the 4th quarter valued at approximately $224,000. Susquehanna International Group LLP raised its holdings in shares of Rapid Micro Biosystems by 12.6% in the third quarter. Susquehanna International Group LLP now owns 58,387 shares of the company’s stock worth $195,000 after buying an additional 6,528 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Rapid Micro Biosystems by 37.8% in the third quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company’s stock worth $186,000 after buying an additional 15,255 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Rapid Micro Biosystems during the fourth quarter valued at $182,000. Institutional investors and hedge funds own 52.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on RPID. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.